Developments in virus-like particle-based vaccines for HIV. (Q38081965)

28 August 2017

Developments in virus-like particle-based vaccines for HIV. (English)

1 reference

28 August 2017

Maria Tagliamonte

2

0 references

Luigi Buonaguro

object named as

Luigi Buonaguro

series ordinal

1

0 references

Maria Lina Tornesello

object named as

Maria Lina Tornesello

series ordinal

4

0 references

Franco M Buonaguro

series ordinal

5

object named as

Franco M Buonaguro

1 reference

28 August 2017

Maria Luisa Visciano

3

1 reference

28 August 2017

1 February 2013

1 reference

Expert Review of Vaccines

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

119-127

1 reference

28 August 2017

2

1 reference

Antiretroviral therapy and management of HIV infection

28 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Salvage antiretroviral therapy in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Clinical management of HIV-1 resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

New paradigms for HIV/AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Heterologous prime-boost vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HIV Vaccines: A Global Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

In vitro gene transfer using human papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particle vaccines and adjuvants: the HPV paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particles as particulate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Influenza vaccines based on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Vaccines that facilitate antigen entry into dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human immunodeficiency virus-like particles activate multiple types of immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Molecular immune signatures of HIV-1 vaccines in human PBMCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Recognition of viruses by innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Role of Toll-like receptors in costimulating cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Virus-like particles production in green plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

DermaVir: a novel topical vaccine for HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

X-ray structures of the hexameric building block of the HIV capsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Can HIV p24 be a suitable scaffold for presenting Env antigens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

HIV p24 as scaffold for presenting conformational HIV Env antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.152

21 January 2018

Identifiers

DOI

10.1586/ERV.12.152

1 reference

release_yhrnx25z2fc7zjyj2ik6hzd2me

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yhrnx25z2fc7zjyj2ik6hzd2me

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

23414404

1 reference

PubMed ID

23414404